The government’s decision to cap trade margins at 30 per cent of the maximum retail price for all non-scheduled anti-cancer medicines is a welcome step towards making cancer treatment more affordable. The move is expected to cover around 110 medicines, including 35 patented drugs, and could reduce prices by up to 70 per cent in some cases. With potential annual savings estimated at Rs 2,500 crore, the measure could ease the financial burden on patients and their families, many of whom spend a substantial part of their savings on prolonged treatment. By covering branded and generic medicines, as well as domestic and imported drugs, the policy seeks to address excessive mark-ups across the pharmaceutical supply chain.
However, lower prices on paper must translate into real savings at pharmacies and hospitals. The government must ensure effective implementation, transparent pricing and strict monitoring to prevent manufacturers or distributors from circumventing the new limits. Equally important is ensuring that price controls do not disrupt the availability of essential medicines or discourage the introduction of new treatments. The experience of the 2019 intervention, which covered select anti-cancer drugs, should help authorities identify gaps and strengthen enforcement under the expanded framework.
Ultimately, affordability must be a central component of cancer care, alongside early diagnosis, quality treatment and access to medical facilities. Even with cheaper medicines, patients may continue to face substantial expenses on surgery, chemotherapy, radiation, hospitalisation and diagnostic tests. The latest decision is therefore an important step, but not a complete solution to the high cost of cancer treatment. Its success will depend on whether the promised reductions reach patients promptly and consistently. A sustained policy combining price regulation, wider health insurance coverage and stronger public healthcare infrastructure is essential to ensure that the ability to pay does not determine a patient’s chance of survival.